A carregar...
Differences Between Managed Care and Fee-for-Service Medicaid in the Use of Generics for High-Rebate Drugs: The Cases of Insulin Glargine and Glatiramer
BACKGROUND: Statutory rebates and preferred drug lists (PDLs) may result in differential use of biosimilars and generics between Medicaid fee-for-service (FFS) and managed care organizations (MCOs), particularly for branded drugs with large price increases subject to large inflation rebates, which a...
Na minha lista:
| Publicado no: | J Manag Care Spec Pharm |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Academy of Managed Care Pharmacy
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7026907/ https://ncbi.nlm.nih.gov/pubmed/32011961 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18553/jmcp.2020.26.2.154 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|